Table 2.
Some major clinical trials targeting cancer vasculature
| Target | Drug | Combination | Condition | Phase | Status | Trial number |
|---|---|---|---|---|---|---|
| VEGF/VEGFR | Bevacizumab | No | Solid tumors | IV | Completed | NCT01588184 |
| Bevacizumab | Chemotherapies | Ovarian cancer | III | Active, not recruiting | NCT00565851 | |
| Bevacizumab | Erlotinib | Lung cancer | II | Completed | NCT01562028 | |
| Bevacizumab | Erlotinib | Hepatocellular Carcinoma | II | Completed | NCT01180959 | |
| Bevacizumab | Niraparib | Ovarian Cancer | I/II | Completed | NCT02354131 | |
| Olaparib | Chemotherapies | Ovarian Cancer | III | Active, not recruiting | NCT02477644 | |
| Olaparib | Enzalutamide, abiraterone acetate | Prostate Cancer | III | Active, not recruiting | NCT02987543 | |
| Bevacizumab | Osimertinib | Lung Cancer | I/II | Completed | NCT02803203 | |
| Bevacizumab | Osimertinib | Lung Cancer | III | Recruiting | NCT04181060 | |
| Ramucirumab | Erlotinib, Gefitinib, Osimertinib | Metastatic NSCLC | III | Active, not recruiting | NCT02411448 | |
| Ramucirumab | Paclitaxel | Gastric Adenocarcinoma | III | Completed | NCT01170663 | |
| Ramucirumab | No | Gastric Cancer and Adenocarcinoma | III | Completed | NCT00917384 | |
| Ramucirumab | No | Hepatocellular Carcinoma | III | Completed | NCT01140347 | |
| Ramucirumab | No | Hepatocellular Carcinoma | III | Completed | NCT02435433 | |
| Ramucirumab | No | Hepatocellular Carcinoma | III | Completed | NCT02435433 | |
| Aflibercept | FOLFIRI | Metastatic Colorectal Cancer | III | Completed | NCT00561470 | |
| Aflibercept | Levofolinate, Irinotecan, 5-FU | Metastatic Colorectal Cancer | II | Completed | NCT01882868 | |
| Aflibercept | Capecitabine | Metastatic Colorectal Cancer | I/II | Completed | NCT01661972 | |
| TKI | Sorafenib | No | Hepatocellular Carcinoma | III | Completed | NCT00692770 |
| Sunitinib | AGS-003 | Kidney Cancer | II | Completed | NCT00678119 | |
| Sunitinib | Nivolumab, Pazopanib, Ipilimumab | Renal Cell Carcinoma | I | Completed | NCT01472081 | |
| Pazopanib | No | Ovarian Cancer | I/II | Completed | NCT01238770 | |
| Pazopanib | No | Renal Cell Carcinoma | IV | Completed | NCT01521715 | |
| Pazopanib | Paclitaxel | Ovarian Cancer | II | Completed | NCT01644825 | |
| Pazopanib | GSK1120212 | Solid Tumors, Thyroid Cancer | I | Completed | NCT01438554 | |
| ANG-VEGF | Vanucizumab | Atezolizumab | Solid Tumors | I | Completed | NCT01688206 |
| Vanucizumab | Bevacizumab, Selicrelumab | Solid Tumors | I | Completed | NCT02665416 | |
| Plus immunotherapy | Bevacizumab | Nivolumab, Rucaparib | Peritoneal Cancer,Ovarian Cancer, Fallopian Tube Cancer | II | Recruiting | NCT02873962 |
| Bevacizumab | Nivolumab and chemotherapies | Non-small Cell Lung Cancer | I | Completed | NCT01454102 | |
| Bevacizumab | Pembrolizumab | Clear Cell Renal Carcinoma | I/II | Completed | NCT02348008 | |
| Bevacizumab | Pembrolizumab | Glioblastoma | II | Completed | NCT02337491 | |
| Bevacizumab | Pembrolizumab | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | II | Completed | NCT02853318 | |
| Bevacizumab | Durvalumab | Glioblastoma | II | Completed | NCT02336165 | |
| Bevacizumab | Durvalumab | Metastatic Breast Cancer | I | Completed | NCT02802098. | |
| Bevacizumab | Tremelimumab | Colorectal Cancer With Liver Metastases | I | Active, not recruiting | NCT02754856 | |
| Vanucizumab | Atezolizumab | Metastatic Solid Tumors | I | Completed | NCT01688206 |